Abstract
Introduction: Anticoagulation for continuous renal replacement therapy (CRRT) can be performed using systemic anticoagulation or regional citrate anticoagulation (RCA). The 2012 Kidney Disease Improving Global Outcomes guidelines support the use of RCA as the first-line strategy in patients requiring CRRT, with and without bleeding risk. Implementing RCA in the intensive care unit (ICU) implies involving all medical and nursing staff. The primary objective of this study was to report and describe the various anticoagulation strategies for CRRT in French ICUs. The secondary objectives were to determine the rate of RCA use and to identify the factors limiting its implementation. Methods: An online questionnaire containing 40 questions was sent to attending physicians and fellows practicing in French ICUs between May and September 2021. The questionnaire was sent via several networks: mailing list from the French Society of Anesthesia and Intensive Care Medicine and mailing lists of RRT manufacturers. Results: A total of 597 responses were analyzed. RCA was used by most of the participants for patients with (81%) and without (80%) increased bleeding risk. The preferred CRRT modality of the participants while using RCA was continuous veno-venous hemodialysis (48%). The clinical situations frequently reported as an absolute contraindication to RCA were uncontrolled shock associated with liver failure and drug poisoning impairing citrate metabolism (62% and 52%, respectively). In case of a higher risk of citrate accumulation, most participants claimed to perform closer biological monitoring (57%) or to modify the CRRT protocol (61%). Among the participants who did not prescribe RCA as a first-line strategy, the main factors limiting its implementation were the lack of nurse (50%) or physician (34%) training. Conclusion: RCA is the main anticoagulation strategy prescribed for CRRT in France. Providing medical and nursing staff easy access to training may facilitate the understanding and use of RCA as the first-line anticoagulation strategy for CRRT.
Journal Section:
Critical Care Nephrology – Research Article
References
1.
Kellum
JA
, Sileanu
FE
, Murugan
R
, Lucko
N
, Shaw
AD
, Clermont
G
. Classifying AKI by urine output versus serum creatinine level
. J Am Soc Nephrol
. 2015
;26
(9
):2231
–8
. 2.
Hoste
EAJ
, Bagshaw
SM
, Bellomo
R
, Cely
CM
, Colman
R
, Cruz
DN
, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study
. Intensive Care Med
. 2015
;41
(8
):1411
–23
. 3.
Ronco
C
, Bellomo
R
, Kellum
JA
. Acute kidney injury
. Lancet
. 2019
;394
(10212
):1949
–64
. 4.
Murugan
R
, Kellum
JA
. Acute kidney injury: what’s the prognosis
. Nat Rev Nephrol
. 2011
;7
(4
):209
–17
. 5.
Uchino
S
. Acute renal failure in critically ill PatientsA multinational, multicenter study
. JAMA
. 2005
;294
(7
):813
. 6.
Nash
DM
, Przech
S
, Wald
R
, O’Reilly
D
. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit
. J Crit Care
. 2017
;41
:138
–44
. 7.
Recommandations KDIGO. 2012 kidney international supplements. 2012;2(1):1.
8.
Uchino
S
, Bellomo
R
, Morimatsu
H
, Morgera
S
, Schetz
M
, Tan
I
, et al. Continuous renal replacement therapy: a worldwide practice survey: the beginning and ending supportive therapy for the kidney (B.E.S.T. Kidney) investigators
. Intensive Care Med
. 2007
;33
(9
):1563
–70
. 9.
Wetering
J
, Westendorp
RG
, van der Hoeven
J
, Stolk
B
, Feuth
JD
, Chang
PC
. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage
. J Am Soc Nephrol
. 1996
;7
(1
):145
–50
. 10.
Oudemans-van Straaten
HM
, Bosman
RJ
, Koopmans
M
, van der Voort
PHJ
, Wester
JPJ
, van der Spoel
JI
, et al. Citrate anticoagulation for continuous venovenous hemofiltration
. Crit Care Med
. 2009
;37
(2
):545
–52
. 11.
Hetzel
GR
, Schmitz
M
, Wissing
H
, Ries
W
, Schott
G
, Heering
PJ
, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial
. Nephrol Dial Transpl
. 2011
;26
(1
):232
–9
. 12.
Zhang
Z
, Hongying
N
. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy
. Intensive Care Med
. 2012
;38
(1
):20
–8
. 13.
Zarbock
A
, Küllmar
M
, Kindgen-Milles
D
, Wempe
C
, Gerss
J
, Brandenburger
T
, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial
. JAMA
. 2020
;324
(16
):1629
–39
. 14.
Quenot
JP
, Amrouche
I
, Lefrant
JY
, Klouche
K
, Jaber
S
, Du Cheyron
D
, et al. Renal replacement therapy for acute kidney injury in French intensive care units: a nationwide survey of practices
. Blood Purif
. 2022
;51
(8
):698
–707
. 15.
Van Vong
L
, Osman
D
, Vinsonneau
C
, Vinsonneau
C
. Épuration extrarénale en réanimation adulte et pédiatrique. Recommandations formalisées d’experts sous l’égide de la Société de réanimation de langue française (SRLF), avec la participation de la Société française d’anesthésie-réanimation (Sfar), du Groupe francophone de réanimation et urgences pédiatriques (GFRUP) et de la Société francophone de dialyse (SFD): Société de réanimation de langue française. Experts Recommandations
. Réanimation
. 2014
;23
(6
):714
–37
. 16.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. 2012;2(1):1.
17.
Morgera
S
, Schneider
M
, Slowinski
T
, Vargas-Hein
O
, Zuckermann-Becker
H
, Peters
H
, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid–base status
. Crit Care Med
. 2009
;37
(6
):2018
–24
. 18.
Khadzhynov
D
, Schelter
C
, Lieker
I
, Mika
A
, Staeck
O
, Neumayer
H-H
, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation
. J Crit Care
. 2014
;29
(2
):265
–71
. 19.
Khadzhynov
D
, Dahlinger
A
, Schelter
C
, Peters
H
, Kindgen-Milles
D
, Budde
K
, et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation
. Crit Care Med
. 2017
;45
(9
):e941
–6
. 20.
Tan
J-N
, Haroon
SWP
, Mukhopadhyay
A
, Lau
T
, Murali
TM
, Phua
J
, et al. Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy
. J Intensive Care Med
. 2019
;34
(5
):418
–25
. 21.
Link
A
, Klingele
M
, Speer
T
, Rbah
R
, Pöss
J
, Lerner-Gräber
A
, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients
. Crit Care
. 2012
;16
(3
):R97
. 22.
Zhang
W
, Du
K
, Chen
X
, Li
L
, Zhao
L
, Sun
S
. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis
. Crit Care
. 2019
;23
(1
):218
. 23.
Schultheiß
C
, Saugel
B
, Phillip
V
, Thies
P
, Noe
S
, Mayr
U
, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study
. Crit Care
. 2012
;16
(4
):R162
. 24.
Slowinski
T
, Morgera
S
, Joannidis
M
, Henneberg
T
, Stocker
R
, Helset
E
, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study
. Crit Care
. 2015
;19
(1
):349
. 25.
Joannes-Boyau
O
, Velly
L
, Ichai
C
. Optimizing continuous renal replacement therapy in the ICU: a team strategy
. Curr Opin Crit Care
. 2018
;24
(6
):476
–82
. 26.
Przybyl
H
, Evans
J
, Haley
L
, Bisek
J
, Beck
E
. Training and maintaining: developing a successful and dynamic continuous renal replacement therapy program
. AACN Adv Crit Care
. 2017
;28
(1
):41
–50
. 27.
Bianchi
NA
, Altarelli
M
, Eckert
P
, Schneider
AG
. Complications of regional citrate anticoagulation for continuous renal replacement therapy: an observational study
. Blood Purif
. 2020
;49
(5
):567
–75
. 28.
Schilder
L
, Nurmohamed
SA
, Bosch
FH
, Purmer
IM
, den Boer
SS
, Kleppe
CG
, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial
. Crit Care
. 2014
;18
(4
):472
. 29.
Jolly
F
, Jacquier
M
, Pecqueur
D
, Labruyère
M
, Vinsonneau
C
, Fournel
I
, et al. Management of renal replacement therapy among adults in French intensive care units: a bedside practice evaluation
. J Intensive Med
. 2023
;3
(2
):147
–54
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
